Abstract: A device for cleaning a finished monocrystalline square rod may include a washer arranged on a side of the square rod for washing the square rod and a dryer arranged around the square rod for blow-drying the washed square rod.

Abstract: The present invention provides an artificially designed antibody molecule comprising four polypeptide chains, where each of the first polypeptide chain and the third polypeptide chain comprises an immunoglobulin light chain, and each of the second polypeptide chain and the fourth polypeptide chain comprises, from the N-terminus to the C-terminus, an immunoglobulin heavy chain variable region, an immunoglobulin CH1 domain, a VHH, an immunoglobulin CH2 domain, an immunoglobulin CH3 domain, and optionally an immunoglobulin CH4 domain. The present invention also provides a polynucleotide encoding the antibody molecule, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, an immunoconjugate and a pharmaceutical composition comprising the antibody molecule, and use of the antibody molecule in the immunotherapy, prevention and/or diagnosis of diseases.

Abstract: An antibody that specifically binds to a glucocorticoid-induced tumor necrosis factor receptor (GITR), an antibody fragment and a polymer thereof, and a conjugate and a fusion comprising the antibody or the antibody fragment are provided in the present invention. A nucleic acid encoding the antibody, the antibody fragment, the polymer, the conjugate and the fusion, a vector, and a host cell expressing the nucleic acid are also provided in the present invention. In addition, a composition comprising the antibody and the antibody fragment thereof, the polymer, the conjugate or the fusion, and use thereof in therapy and diagnosis are also provided in the present invention.

Abstract: An antibody that specifically binds to a glucocorticoid-induced tumor necrosis factor receptor (GITR), an antibody fragment and a polymer thereof, and a conjugate and a fusion comprising the antibody or the antibody fragment are provided in the present invention. A nucleic acid encoding the antibody, the antibody fragment, the polymer, the conjugate and the fusion, a vector, and a host cell expressing the nucleic acid are also provided in the present invention. In addition, a composition comprising the antibody and the antibody fragment thereof, the polymer, the conjugate or the fusion, and use thereof in therapy and diagnosis are also provided in the present invention.

Abstract: The present invention provides a novel artificial triple-chain antibody comprising three polypeptide chains, wherein a first polypeptide chain comprises a first heavy-chain variable domain, a second polypeptide chain comprises a first light-chain variable domain that is paired with the first heavy-chain variable domain to form a first antigen-binding site; and a third polypeptide chain comprises a second single-domain antigen-binding site and a third single-domain antigen-binding site. The present invention also provides a polynucleotide encoding the triple-chain antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, an immunoconjugate comprising the triple-chain antibody and a pharmaceutical composition comprising the triple-chain antibody or the immunoconjugate thereof, and use of the triple-chain antibody in immunotherapy, prevention and/or diagnosis of diseases.

Abstract: The present invention relates to a novel single-domain antibody and a fragment thereof that specifically bind to PD-L1 and a composition comprising the antibody or the fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or the fragment thereof, a host cell comprising the nucleic acid, and related uses. Furthermore, the present invention relates to therapeutic and diagnostic uses of the antibody and the fragment thereof. In particular, the present invention relates to combination therapies of these antibodies and the fragments thereof with other therapies, such as therapeutic modalities or therapeutic agents.

Abstract: The present invention provides a novel, artificially designed antibody molecule comprising: (i) single-domain antigen-binding sites; (ii) antigen-binding Fab fragments; wherein the single-domain antigen-binding site is located at the N-terminus of a light chain variable domain (VL) of the antigen-binding Fab fragment or the C-terminus of a light chain constant region (CL) of the antigen-binding Fab fragment or the single-domain antigen-binding site is located at the N-terminus of a heavy chain variable domain (VH) or the C-terminus of an immunoglobulin CH1 domain of the antigen-binding Fab fragment, the single-domain antigen-binding site and the antigen-binding Fab fragment bind to the same antigen or different antigens, and the single-domain antigen-binding site and the antigen-binding Fab fragment have or do not have a linker peptide therebetween; and (iii) immunoglobulin Fc domains located at the C-terminus of the single-domain antigen-binding site or the antigen-binding Fab fragment.